Compare AMCX & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMCX | EVO |
|---|---|---|
| Founded | 1980 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.0M | 568.6M |
| IPO Year | 2011 | 2007 |
| Metric | AMCX | EVO |
|---|---|---|
| Price | $10.93 | $1.56 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $9.83 | $4.17 |
| AVG Volume (30 Days) | ★ 553.5K | 158.0K |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.55 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,311,801,000.00 | N/A |
| Revenue This Year | $5.07 | N/A |
| Revenue Next Year | N/A | $20.51 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.47 | $1.50 |
| 52 Week High | $12.93 | $4.27 |
| Indicator | AMCX | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 36.88 | 36.94 |
| Support Level | $9.23 | $1.50 |
| Resistance Level | $11.13 | $1.97 |
| Average True Range (ATR) | 0.40 | 0.07 |
| MACD | -0.14 | 0.01 |
| Stochastic Oscillator | 14.16 | 22.00 |
AMC Global Media owns several linear TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network,reached 55 million pay TV households in the US at the end of 2025. The firm also had nearly 10.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.